|
|
|
| 06:56 |
NSIT Insight Enterprises authorizes additional $400 mln stock repurchase program - 8-K filing
(168.76 )
|
|
- Board approved a new authorization to repurchase up to $400.0 mln of common stock.
- The new program is in addition to about $36.5 mln that remained available under prior authorizations as of Nov. 4, 2026.
- Disclosure was made in an Item 8.01 filing dated Nov. 16, following board approval on Nov. 13, 2026.
- SEC filing
|
|
| 06:53 |
MDLN Medline launches secondary offering of 60M Class A shares; selling holders to grant 9M-share option
(39.47 )
|
|
- Selling stockholders affiliated with Blackstone (BX), Carlyle (CG), Hellman & Friedman, GIC and ADIA commenced an underwritten public offering of 60,000,000 Class A shares.
- Medline is not selling any shares and will not receive any proceeds from the offering.
- Selling stockholders also intend to grant underwriters a 30-day option to buy up to 9,000,000 additional shares.
- Separately, Medline and Medline Holdings agreed to repurchase an aggregate of $200 mln of Class A stock and common units from the selling stockholders, expected to close concurrently with and conditioned on the offering.
|
|
| 06:45 |
ARMK Aramark authorizes new $1 bln share repurchase program, raises quarterly dividend 17% - 8-K filing
(53.94 )
|
|
- Board approved a new $1 bln buyback program that replaces Aramark's existing $500 mln repurchase authorization.
- Company also raised its quarterly dividend by 17%, citing stronger financial flexibility after fiscal 2026 performance.
- Aramark said the capital return actions follow fiscal 2026 revenue growth of 9% to $20.1 bln and GAAP EPS growth of 33% to $1.62.
- Management said the company plans to keep returning capital while continuing to invest strategically in the business.
- SEC filing
|
|
| 06:45 |
MDT Medtronic to acquire Contego Medical for $380 mln plus potential post-close payments
(102.86 )
|
|
- Medtronic said it plans to buy privately held Contego Medical, adding carotid artery disease and peripheral thrombectomy devices to its cardiovascular portfolio.
- The deal includes the recently FDA-approved Neuroguard IEP Direct System, which Medtronic said is the first transcarotid artery revascularization system with integrated embolic protection in addition to flow reversal.
- Contego's Excipio thrombectomy devices will also be added and are expected to complement Medtronic's Liberant system in peripheral vascular disease.
- Medtronic expects to close the transaction in fiscal Q3, subject to customary conditions; the deal is expected to be minimally dilutive to adjusted EPS in FY27 and FY28 and neutral to accretive thereafter.
|
|
| 06:45 |
FANG Diamondback Energy to acquire Double Eagle Midland Basin assets for stock and cash
(184.93 )
|
|
- Diamondback agreed to acquire certain Double Eagle subsidiaries for about 15.56M Diamondback shares plus $2.15 bln in cash, subject to customary adjustments.
- The assets include about 176,000 net acres in the core Midland Basin, estimated 2027 oil production of 35 MBo/d and more than 1,200 estimated gross horizontal locations.
- Diamondback values the deal at about 4.0x estimated 2027 EBITDA and said it will be immediately accretive to cash flow/share, free cash flow/share and NAV/share while remaining leverage neutral.
- The cash portion is expected to be funded with cash on hand, credit facility borrowings and/or term loans; closing is expected Dec. 21, 2026, subject to customary conditions.
|
|
| 06:45 |
GVA Granite completes Utah, Tennessee acquisitions to expand materials and Southeast platform
(124.52 )
|
|
- Granite closed two separate deals on Nov. 13, acquiring Construction Materials Company in Utah and Ford Construction-related businesses in Tennessee.
- CMC adds three aggregate facilities, five ready-mix plants and about 780M tons of estimated aggregate reserves/resources; Granite sees 2027 revenue above $75 mln with adjusted EBITDA margin in the mid-to-low 20s.
- Ford Construction adds four hot-mix asphalt plants, three sand-and-gravel sites and about 46M tons of estimated sand and gravel resources; Granite expects about $100 mln of 2027 revenue with adjusted EBITDA margin above 20%.
- Granite said the deals deepen vertical integration in Utah and extend its Southeast platform in west Tennessee across paving, bridge, marine, transportation and materials operations.
|
|
| 06:37 |
NINE Nine Energy announced that it has entered into a definitive agreement to acquire American Cementing, LLC
(7.42 )
|
|
- The transaction represents a significant step forward in Nine's strategy and will meaningfully expand its cementing business and footprint into the Rockies, Bakken and Northeast.
- The combination is expected to increase Nine's revenue by more than 35%, with American Cementing contributing $200 million of additional annual revenue.1 For the year ended December 31, 2025, American
- Cementing generated revenue of approximately $206.6 million, net income of approximately $18.4 million and Adjusted EBITDA2 of approximately $17.0 million.
- Nine has initially identified approximately $2 million to $5 million of annual synergies expected in 2027, with additional upside potential as the businesses are integrated. The transaction is also expected to be de-leveraging and increase availability under Nine's asset-based revolving credit facility by approximately $25 million, providing added liquidity and greater financial flexibility to support the combined company's operations and growth.
|
|
| 06:30 |
CLW Clearwater Paper names Matt Passarello CFO, reaffirms Q4 adjusted EBITDA guidance
(14.56 )
|
|
- Passarello becomes SVP and CFO effective Nov. 14 under the board's succession plan; he previously led supply chain and corporate development and earlier was a partner in McKinsey's paper and packaging practice.
- Rebecca Barckley was appointed VP, corporate controller and chief accounting officer effective Nov. 14; she has served as VP and corporate controller since 2020.
- Clearwater said repairs at the Augusta, Ga. mill are largely complete and operations are returning to normal; the planned major maintenance outage remains set for January 2027, while the Cypress Bend, Ark. outage has been completed.
- The company reaffirmed Q4 2026 adjusted EBITDA guidance of $10 mln-$20 mln and now sees 2026 capex of $50 mln-$55 mln, partly due to postponing the Augusta annual outage into early 2027.
|
|
| 06:30 |
SCANX Early premarket gappers |
|
- Gapping up:
- DRTS +14.4%, HTHT +6.8%, RLMD +6.7%, OCS +6.5%, INCY +4.9%, ACCV +4.6%, XPEV +3.3%, MOH +3.1%, CNC +2.5%, ETRA +2.4%, RCUS +2.3%, CHYM +2.3%, BMI +2.2%, BOC +2.0%, MANU +2.0%, ONB +1.8%, ZYME +1.8%, QSR +1.8%, ALHC +1.8%, ELV +1.7%, TAK +1.7%, EVGO +1.7%, SYY +1.7%, DNOW +1.6%, STLA +1.6%, UHS +1.5%, CB +1.5%, GLOO +1.4%, AKR +1.3%, HTZ +1.3%, NVO +1.3%, HCA +1.2%, TM +1.2%, CVI +1.1%, CG +1.1%, JNJ +1.0%
- Gapping down:
- SMMT -18.7%, ACRS -15.3%, IEP -11.4%, CRWV -6.5%, TE -6.3%, NBIS -5.4%, EROC -5.4%, GDS -5.1%, SKHY -5.0%, WULF -4.9%, GLXY -4.8%, DELL -4.7%, MRVL -4.7%, FPS -4.7%, CLS -4.5%, MU -4.5%, ENRD -4.5%, INBX -4.5%, INTC -4.4%, FIGR -4.3%, AMD -4.3%, JBLU -4.3%, AAPG -4.2%, CBRS -4.1%, TSM -4.1%, VSH -3.9%, MRAM -3.9%, AMAT -3.9%, STX -3.8%, KDK -3.6%, GLW -3.6%, LGN -3.5%, LHX -3.4%, SVC -3.3%, FRVO -3.3%, KEEL -3.2%, RKLB -3.1%, AVGO -3.0%, FTCI -2.9%, HUN -2.7%, YSWY -2.6%, INIO -2.5%, ECHO -2.5%, WCC -2.4%, QNT -2.4%, HAWK -2.4%, NVDA -2.3%, ZETA -2.2%, ORCL -2.2%, ON -2.2%
|
|
| 06:26 |
S&P futures vs fair value: -18.00. Nasdaq futures vs fair value: -205.00. |
|
|
|
| 06:26 |
European Markets |
|
FTSE...10937.12...+34.60...+0.30%. DAX...26727.2...-90.50...-0.30%. |
|
| 06:26 |
Asian Markets |
|
Nikkei...59662.02...-1480.30...-2.40%. Hang Seng...23753.84...+116.20...+0.50%. |
|
| 06:16 |
BIDU Baidu beats Q3 EPS estimates; revenue falls 1% yr/yr amid online advertising weakness
(78.14 )
|
|
- Baidu reports Q3 (Sep) non-GAAP EPS of RMB6.78 versus RMB6.03 FactSet consensus; revenue declined 1% yr/yr to RMB30.81 bln versus RMB30.91 bln consensus. Non-GAAP operating income was RMB1.7 bln, with an operating margin of 6%.
- AI Cloud Infrastructure revenue surged 94% yr/yr to RMB8.2 bln, including 191% growth in GPU Cloud revenue. Baidu Core AI-powered Business revenue increased 37% to RMB13.2 bln, accounting for 53% of Baidu General Business revenue.
- Online Marketing Services revenue declined 22% yr/yr to RMB11.9 bln, while AI-native marketing revenue fell 15% to RMB2.4 bln. Baidu General Business revenue increased 1% to RMB25.0 bln, partially offsetting a 10% decline in iQIYI revenue to RMB6.0 bln.
- Adjusted EBITDA was RMB4.5 bln, with a 15% margin. Operating cash flow totaled RMB2.8 bln, while total cash and investments reached RMB276.6 bln ($41.25 bln). Co has repurchased $373 mln in shares since the beginning of 2026 and expects to declare its first dividend before year-end, subject to approval.
|
|
| 06:08 |
LHX L3Harris issues statement on the Nov. 13 ground stop
(272.35 )
|
|
- "L3Harris has been modernizing the communications infrastructure supporting the National Airspace System in close coordination with the FAA. With safety and reliability as our highest priorities, L3Harris, together with its telco partners and the FAA, has completed more than 70% of the planned airspace communications conversion from legacy copper wires to a fiber optic system.
- We are supporting the FAA in its investigation to understand the conditions that led to the Nov. 13 ground stop of our nation's air travel. L3Harris takes the nationwide ground stop and its impact on travelers, airlines and air traffic operations seriously."
|
|
| 06:05 |
BBY Best Buy Canada partners with Uber Eats for on-demand electronics delivery nationwide
(104.07 )
|
|
- Uber (UBER) will become Best Buy Canada's exclusive third-party delivery marketplace for the first year, adding Best Buy to the Uber Eats app across Canada.
- Customers can shop from just under 300 Best Buy locations through Uber Eats, with eligible electronics orders delivered in as little as 30 minutes.
- The offering launches ahead of the holiday season and includes products such as laptops, tablets, headphones, gaming accessories and chargers.
- Uber One members get $0 delivery fee on eligible Best Buy orders with a minimum purchase, subject to terms.
|
|
| 06:05 |
ALMR Alamar Biosciences highlights NULISA data in 46 presentations at CTAD 2026, including 10 oral presentations
(30.81 )
|
|
Fremont, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data generated with its NULISA precision proteomic platform will be featured in 46 presentations, including 10 oral presentations, at the Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16 to 19, 2026, in Boston. |
|
| 06:04 |
KMTS Kestra announces publication of ACE-PAS, the largest prospective real-world wearable defibrillator study, in the journal of cardiovascular electrophysiology
(28.64 )
|
|
KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk. |
|
| 06:02 |
MWH SOLV Energy continues to expand its role as a full-lifecycle infrastructure services provider supporting customers across construction, operations, maintenance and asset optimization
(27.81 )
|
|
- RE+ 2026 marks SOLV's first appearance at the industry's largest clean energy conference since becoming a publicly traded company earlier this year.
- "The need for reliable, scalable power continues to grow, creating opportunities across every stage of the energy asset lifecycle," said George Hershman, Chief Executive Officer of SOLV Energy. "Customers are looking for partners that can deliver projects successfully and support long-term asset performance. From engineering through operations, maintenance and repowering, SOLV is uniquely positioned to meet those needs."
- SOLV continues to see strong demand for large-scale energy infrastructure projects across North America, with average project size now exceeding 400 MWdc, resulting in a robust backlog of $9.2B as of September 30, 2026, with the Southwest, South-Central and Midwest regions driving growth.
|
|
| 06:02 |
META Meta introduces Dream Render AI video app for small businesses and creators
( )
|
|
- Meta launched Dream Render, a browser-based AI web app that turns a product photo or short description into a first-draft product video in minutes.
- Users can edit shots, framing, pacing, voiceover and on-screen text, then preview, approve, download and publish the final video; videos carry an AI-made label.
- The tool is available at dreamrender.com with sign-in via a Facebook profile or Instagram professional account, with no download or installation required.
- The announcement came alongside Meta Upskill Day in Singapore, where the company also highlighted demand for more AI guidance among surveyed small-business owners.
Company blog |
|
| 06:00 |
AVR Anteris says one-year DurAVR THV data in 100 patients to be presented at PCR London Valves
(5.42 )
|
|
- Anteris said late-breaking one-year clinical and hemodynamic outcomes for its DurAVR transcatheter heart valve will be presented at PCR London Valves on Nov. 22.
- The presentation will cover a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV.
- Data will be presented by Rishi Puri of Cleveland Clinic during the TAVI Hotline late-breaking trials session in London.
- The release announces an upcoming data presentation and does not disclose the one-year results.
|
|
| 06:00 |
EGAN eGain launches Trusted Knowledge Service for AI readiness across existing enterprise content platforms
(6.20 )
|
|
- eGain introduced a new service to assess, remediate, validate and manage enterprise knowledge so AI systems can deliver more trusted answers without replacing existing platforms.
- The offering starts with a two-week read-only assessment and can extend to remediation, side-by-side proof testing and managed AI KnowledgeOps.
- eGain said the service supports SharePoint, Confluence, ServiceNow, Salesforce Knowledge, and PDF and document stores.
- Company said all fees are credited toward ongoing eGain products or services.
|
|
| 06:00 |
ZYME Zymeworks authorizes new $200 mln share repurchase program through 2028
(26.24 )
|
|
- Board approved a second 2026 buyback program for up to $200 mln of common stock; Zymeworks expects to repurchase about $140 mln through 2028.
- Company said it plans to start the program before year-end 2026 after completing its initial $125 mln 2026 repurchase authorization.
- Funding is expected from the existing balance sheet, about $55 mln of upfront fees tied to the Roche collaboration closing, and a potential $100 mln TRELEGY ELLIPTA milestone in Q1 2027.
- Repurchases may be made in the open market or under Rule 10b5-1 plans; the program can be suspended or discontinued at any time and does not require any set amount of purchases.
|
|
| 06:00 |
SUMRX The Overnight Summary - US futures slide to start the week |
|
- Wall Street is bracing for a defining week for the AI trade, with Nvidia's first earnings report since Jensen Huang's ouster and Anthropic's potentially record-breaking IPO set to test investor confidence. Renewed speculation over Huang's possible return is adding to the uncertainty, with Nasdaq futures under pressure ahead of the two major catalysts. The S&P (Dec) is down about 26 points, trading around 7557 after an early advance stalled at 7614.25. Selling pressure persisted throughout the Asian session, pushing futures to an overnight low of 7537.75 near the close of regional trading before a modest rebound during the European session lifted the contract off its lows.
- Asian markets finished mostly lower on Monday, with technology and semiconductor shares bearing the brunt of selling pressure amid concerns over AI valuations and the industry's near-term outlook. Japan's Nikkei 225 fell 2.4%, with Advantest (-11.1%), Taiyo Yuden (-10.0%), Kioxia Holdings (-7.7%), Tokyo Electron (-7.1%), and SoftBank Group (-3.7%) leading the decline, while an unexpected annualized contraction in third-quarter GDP added to concerns over weak domestic demand. China's Shanghai Composite declined 0.9% and the Shenzhen Component dropped 2.5%, with Zhongji Innolight (-12.3%), Eoptolink Technology (-11.1%), Cambricon Technologies (-8.3%), and Hygon Information Technology (-6.5%) retreating amid continued selling in AI-related stocks. Chinese industrial production slowed to 4.8% year-over-year in October from 5.5% in September, while retail sales growth weakened to just 0.4% from 1.1%, reinforcing concerns about the pace of the country's economic recovery. Hong Kong's Hang Seng Index bucked the regional trend, gaining 0.5% as bargain hunting lifted Meituan (+2.8%), AIA (+1.8%), Tencent (+0.8%), and Xiaomi (+0.4%) following last week's losses. Investors also looked ahead to the November 19 meeting between Presidents Trump, Xi, and Putin in Shenzhen, with trade relations and potential technology restrictions among the key issues in focus. South Korea's KOSPI tumbled 3.6%, with SK Square (-3.9%), SK Hynix (-2.3%), Doosan Enerbility (-2.0%), and LG Energy Solution (-1.4%) retreating, while Samsung Electronics (-0.2%) also finished lower. Separately, SK Hynix announced plans for a KRW 874.6 billion semiconductor testing facility scheduled to open in May 2027, aimed at strengthening the domestic chip supply chain.
- European markets trade modestly higher, with defensive, aerospace, and luxury shares providing support despite broader caution surrounding the technology sector. Germany's DAX 40 trades flat near record highs, with Rheinmetall (+2.2%), MTU Aero Engines (+1.3%), Fresenius (+1.0%), and Deutsche Telekom (+0.8%) advancing, while Siemens (-2.3%), Infineon Technologies (-1.9%), and Siemens Energy (-0.6%) lag. France's CAC 40 gains 0.2%, supported by Dassault Aviation (+1.3%), Thales (+1.2%), and Herms (+1.0%), while STMicroelectronics (-1.1%) retreats amid continued pressure on semiconductor shares following Nvidia's leadership shakeup. London's FTSE 100 rises 0.3%, supported by strength in mining and defense stocks, although hawkish comments from Bank of England Chief Economist Huw Pill temper gains ahead of UK inflation data later this week. Pill suggested additional interest rate hikes may be necessary in 2027 following an anticipated increase next month, reinforcing expectations for a prolonged period of restrictive monetary policy. Among individual UK movers, Legal & General (-2.0%) declines despite reaffirming its targets and announcing plans to eliminate approximately 1,000 jobs by mid-2027, while Centrica (-1.0%) retreats following developments in the sale process for German utility Uniper.
Market Updates - S&P Futures: -26.0
- 10 yr Note: 5.143% -0.002
- USD/JPY: 159.68 +0.01
- EUR/USD: 1.1011 -0.0024
- Europe: FTSE: +0.3% DAX: 0.0% CAC: +0.2%
- Asia: Hang Seng: +0.5% Shanghai: -0.9% Nikkei: -2.4% KOSPI -3.6%
- Gold (3867.10 -19.20) Silver (47.665 -1.456) Crude (88.48 -0.08)
|
|
| 05:35 |
CNQ Canadian Natrl Res to acquire Advantage Energy for $2.53 bln
(49.75 )
|
|
- Canadian Natural Resources announces a definitive agreement to acquire Advantage Energy for C$13.55 per share in cash, representing approximately C$2.26 bln in equity value and C$2.53 bln in total transaction value, including net debt and outstanding convertible debentures.
- The acquisition adds approximately 79,000 barrels of oil equivalent per day (BOE/d) of production from Montney and Charlie Lake assets in Alberta, implying a purchase price of roughly C$32,000 per flowing BOE/d.
- Co expects the transaction to be accretive, with opportunities for operating efficiencies from assets adjacent to its existing Grande Prairie operations. The acquisition will be funded through cash on hand and existing bank credit facilities.
- The transaction is expected to close in Q1 2027, subject to customary conditions. Co intends to maintain its previously announced capital allocation policy, targeting 100% of free cash flow for share repurchases, subject to market conditions.
|
|
| 05:33 |
SDZNY Sandoz launches Enzeevu biosimilar in U.S., signs multi-year private-label agreement
(100.76 )
|
|
- Sandoz announces the U.S. launch of Enzeevu (aflibercept-abzv) 2 mg in a prefilled syringe for retinal diseases, including wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema and macular edema following retinal vein occlusion.
- Co also entered into a multi-year private-label agreement to manufacture Enzeevu for U.S. commercialization beginning in mid-2027, with committed purchase volumes starting in 2H27. Financial terms were not disclosed.
- Enzeevu, approved by the FDA in August 2024, is an interchangeable biosimilar to Regeneron's (REGN) Eylea, with comparable efficacy and safety across approved indications.
- The launch expands Co's ophthalmology portfolio alongside Cimerli and Afqlir, targeting a U.S. anti-VEGF market estimated at $9.6 bln.
|
|
| 05:15 |
AZN AstraZeneca receives positive CHMP opinion for Baxfendy in adults with uncontrolled hypertension
(184.45 )
|
|
- AstraZeneca announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Baxfendy (baxdrostat) for adults with hypertension inadequately controlled by at least two antihypertensive medications.
- In the Phase III BaxHTN trial, Baxfendy 2 mg reduced seated systolic blood pressure by 15.7 mmHg from baseline at week 12, representing a placebo-adjusted reduction of 9.8 mmHg (p<0.001).
- In the Phase III Bax24 trial, the 2 mg dose reduced 24-hour ambulatory systolic blood pressure by 16.6 mmHg from baseline at week 12, with a placebo-adjusted reduction of 14.0 mmHg (p<0.0001). Co reported no unexpected safety findings across the trials.
- If approved, Baxfendy would become the first aldosterone synthase inhibitor authorized in the EU. The therapy is already approved in the U.S. and other markets, with regulatory reviews ongoing in Japan and China.
|
|
| 05:12 |
AZN AstraZeneca receives EU approval for Klygefa in adults with generalized myasthenia gravis
(184.45 )
|
|
- AstraZeneca announces that its Alexion rare disease unit has received European Commission approval for Klygefa (gefurulimab) as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG).
- Approval is based on the Phase III PREVAIL trial, which met its primary endpoint with a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores at week 26 versus placebo (treatment difference of -1.6 points; p<0.0001). Improvements were observed as early as week one and sustained through week 26.
- Klygefa becomes the first dual-binding nanobody C5 inhibitor approved in the EU, offering once-weekly subcutaneous self-administration via autoinjector. The treatment was generally well-tolerated, with a safety profile consistent with previously studied C5 inhibitors.
- Co estimates approximately 66,000 patients across five major European countries have AChR-positive gMG. Klygefa is already approved in the U.S., Japan and other markets, with regulatory reviews ongoing in China and additional countries.
|
|
| 05:07 |
OCS Oculis Holding receives FDA IND clearance for Privosegtor in acute multiple sclerosis relapses
(7.64 )
|
|
- Oculis announces that the FDA has cleared its Investigational New Drug (IND) application for Privosegtor, allowing Co to advance clinical development of the investigational neuroprotective therapy in patients experiencing acute multiple sclerosis (MS) relapses.
- The FDA supported a development strategy encompassing optic neuritis and other MS relapses, including those affecting mobility, with a potential primary endpoint as early as three months. The proposed regimen uses a 3 mg/kg daily dose for five days, consistent with the ongoing PIONEER-1 trial.+
- The clearance builds on Co's Phase II ACUITY trial in optic neuritis, which demonstrated improvements in visual function, preservation of retinal nerve cell integrity and reductions in biomarkers associated with nerve injury and inflammation.
- Co estimates approximately 170,000 MS relapses occur annually in the U.S. and plans to provide additional details on the Privosegtor development program at its December 8, 2026, R&D Day.
|
|
| 05:05 |
EVO Evotec SE receives $2.9 mln Gates Foundation grant to expand stem cell-based drug safety testing
(1.58 )
|
|
- Evotec announces that it has secured a $2.9 mln grant from the Gates Foundation to extend its human stem cell-based drug safety testing program for an additional three years.
- The funding supports the use of Co's New Approach Methodologies (NAMs) platform to identify potential fetal developmental risks associated with investigational drug candidates earlier in the discovery process.
- Co's platform combines human induced pluripotent stem cell models with large-scale screening capabilities to assess developmental safety and support drug candidate selection, potentially reducing reliance on animal testing.
- The grant extends a collaboration initiated in 2023, during which Co screened more than 5,000 compounds across nine Gates Foundation grantee programs.
|
|
| 05:04 |
RHHBY Roche Hldg receives FDA approval for Gazyva as first treatment for primary membranous nephropathy
(60.30 )
|
|
- Roche announces that the FDA has approved Gazyva/Gazyvaro (obinutuzumab) for adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first FDA-approved treatment specifically for the rare autoimmune kidney disorder.
- Approval is supported by the Phase III MAJESTY trial, in which Gazyva achieved complete remission of proteinuria in 36.1% of patients at 104 weeks, compared with 5.7% receiving tacrolimus (p<0.001).
- Co also reported higher overall remission rates at 104 weeks (50.0% vs. 12.9%) and complete remission rates at 76 weeks (36.1% vs. 8.6%). No new safety signals were identified.
- The approval marks Gazyva's third FDA authorization for an immune-mediated kidney disease, following idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while European regulatory reviews are ongoing.
|
|
| 05:01 |
ECONX Fed Governor Michael S. Barr gives speech titled "Some Potential Financial Stability Implications of Artificial Intelligence" |
|
- AI investment financing warrants close monitoring. Barr said the equity premium is low relative to historical norms, though not nearly as low as during the dot-com boom, leaving scope for a significant repricing if AI returns disappoint. On-balance-sheet debt of the seven largest AI firms has grown significantly in 2026 and is expected to exceed $800 billion before year-end. The potential maximum nominal value of long-term contracts, leases, residual value guarantees, and other off-balance-sheet obligations now exceeds $3 trillion. Barr warned that opaque and complex structures can exacerbate selloffs because investors may not know where risk resides.
- Circular financing and market leverage could amplify an AI repricing. Hyperscalers and large GPU producers have more than $100 billion in cumulative equity investments in LLM labs and cloud-computing startups, which often use those funds to purchase compute from their investors. Larger firms also provide collateral backstops for asset-based financing, potentially absorbing losses if borrowers default and data centers or GPUs are liquidated. Barr is less concerned about direct losses because debt backing the boom remains limited, but said high hedge fund leverage and broader risk appetite could produce rapid deleveraging and self-reinforcing fire sales. Strong capital at the largest banks provides a bulwark, though prime brokerage and other counterparty exposures could rise during equity volatility.
- AI trading could improve efficiency but increase systemic herding. Barr said generative AI can broaden data processing, lower barriers to advanced trading technology, improve surveillance, and support market efficiency and integrity. Large-scale autonomous generative-AI trading is not yet occurring, but reliance on similar models and training data could synchronize strategies and reactions to news. Shared flaws or manipulation of trades, quotes, or news could then disrupt many systems simultaneously. He also cited research showing that some reinforcement-learning algorithms can independently develop collusive behavior, spoof markets, or create and exploit bubbles.
- AI raises cyber threats even as it strengthens defenses. Barr said recent incidents show AI models can treat security boundaries as obstacles rather than rules and exploit vulnerabilities previously considered too difficult to attack. Risks include dependence on common platform providers, newly discovered vulnerabilities, and AI-generated deepfakes. Defenders are also using AI to identify and patch weaknesses faster, but Barr noted the structural disadvantage that attackers need to succeed only once while defenders must be right all the time.
Full Speech |
|
| 05:00 |
EEFT Euronet partners with Santander's Getnet to embed tax-free VAT refund processing at payment terminals
(71.11 )
|
|
- Euronet will integrate its Tax Free technology into Getnet's payment terminals for merchants in Spain, adding VAT refund processing directly into the checkout flow.
- The Android-based terminal app combines payment acceptance and Tax Free document issuance on one device, reducing separate hardware and manual steps.
- The system can flag potential VAT-refund eligibility based on the payment card's country and guide store staff through generating and printing required documentation.
- Getnet is Santander's merchant payments platform and a leading acquirer in Iberia; the companies said the rollout is aimed at merchants serving international travelers.
|
|
| 04:58 |
DRTS Alpha Tau reports 100% response rate in initial six evaluable patients in Phase I/II recurrent glioblastoma trial
(13.38 )
|
|
- Alpha Tau Medical announces updated interim results from its U.S. REGAIN trial evaluating Alpha DaRT in recurrent glioblastoma, with all eight treated patients alive as of November 11 and median overall survival not yet reached. Median follow-up among the six evaluable patients was 6.9 months.
- All six evaluable patients achieved an objective response under RANO criteria, including five complete responses (83.3%) and one partial response (16.7%) with a 58% reduction in tumor measurements. Responses in the three most recently assessed patients remain subject to confirmation.
- Co achieved 100% procedural feasibility, successfully deploying Alpha DaRT sources in all eight patients, with no unanticipated serious adverse events. One previously reported Grade 3 seizure-related event resolved, while follow-up imaging identified asymptomatic radiation necrosis or suspected necrosis in four patients.
- No definitive local tumor recurrence has been observed, although imaging findings in two patients remain inconclusive between radiation necrosis and disease progression. Enrollment continues toward a planned 20 patients, with Co hosting a conference call November 16 at 8:30 ET to discuss the findings.
|
|
| 04:56 |
VKTX Viking Therapeutics highlights clinical data from VK2735 Obesity Program at ObesityWeek 2026
(29.22 )
|
|
SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek, taking place from November 14--17, 2026, in Washington, D.C. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity. |
|
| 04:50 |
NVO Novo Nordisk reports reduced food-related thoughts among Wegovy users in real-world studies
(41.63 )
|
|
- Novo Nordisk announces real-world data from the SIGNAL and OCTANE studies showing that Wegovy (semaglutide) injection and oral semaglutide were associated with reductions in "food noise," defined as persistent, unwanted thoughts about food, among adults with overweight or obesity.
- In the SIGNAL study involving 26,213 treatment-nave adults, food noise scores declined within the first month of initiating injectable semaglutide, with an adjusted mean reduction of 0.42 points. The improvement persisted through six months, when scores were 0.72 points below baseline.
- In the OCTANE study, adults initiating oral semaglutide reported an approximately 25% reduction in average food noise scores over three months, from 2.8 to 2.1 (p<0.001). Additionally, 86.4% reported at least one treatment-related improvement, including better-fitting clothing, healthier eating habits and increased physical activity.
- The findings were presented at ObesityWeek 2026 and derived from retrospective analyses of patient-reported data collected through the Ro telehealth platform. Co cautioned that the observational studies establish associations rather than causation and are subject to self-reporting and selection biases.
|
|
| 04:49 |
LLY Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
(1,443.50 )
|
|
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes |
|
| 04:41 |
NVO Novo Nordisk reports approximately 21% weight loss with lower-dose CagriSema in Phase III REDEFINE 9 trials
(41.63 )
|
|
- Novo Nordisk announces that its investigational obesity treatment CagriSema achieved estimated average weight loss of 20.7% and 21.0% at doses of 1.7 mg/1.7 mg and 1.0 mg/1.0 mg, respectively, compared with 2.0% for placebo at week 68 in the Phase III REDEFINE 9 trial (p<0.0001 for both). Results assume all patients remained on treatment.
- Under the treatment regimen estimand, which accounts for treatment discontinuation and rescue interventions, average weight loss was 19.4% and 18.6%, respectively, compared with 4.6% for placebo. The trial was not powered to compare efficacy between the two CagriSema doses.
- At the higher and lower doses, 51.3% and 48.3% of patients, respectively, achieved at least 20% weight loss under the efficacy estimand, compared with 2.7% for placebo. Gastrointestinal adverse events were generally mild to moderate, with treatment discontinuation rates of 2.9% and 4.9%, respectively.
- Co submitted an FDA application for the higher-dose CagriSema 2.4 mg/2.4 mg regimen in December 2025, with a regulatory decision expected in Q4 2026. The REDEFINE 9 findings were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.
|
|
| 04:34 |
SVC Service Properties Trust receives shareholder support for planned transition to triple net lease REIT
(5.70 )
|
|
- Service Properties Trust announces that institutional shareholder Flat Footed LLC has expressed support for Co's plan to transition into a pure-play triple net lease REIT over the next two years.
- Co intends to begin selling its remaining 77 hotels in 2027, targeting the disposition of substantially all properties by the end of 2028 as it exits the hotel ownership business.
- The transition is expected to reduce leverage to no more than 5.0x net debt to Adjusted EBITDA, with hotel dispositions timed to capture potential improvements in property-level EBITDA.
- Flat Footed also expressed support for capital allocation across RMR Group (RMR)-managed entities, noting that RMR client REITs have sold approximately $3.6 bln in assets since 2021, including more than $1.9 bln by SVC.
|
|
| 04:30 |
GSK GSK's ViiV Healthcare receives positive CHMP opinions for expanded pediatric HIV indications for Tivicay and Dovato
(50.45 )
|
|
- GSK announces that its majority-owned ViiV Healthcare has received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to expand the use of Tivicay (dolutegravir) and Dovato (dolutegravir/lamivudine) in younger children living with HIV.
- The CHMP recommends extending Tivicay's dispersible tablet indication to include full-term newborns from birth weighing at least 2 kg. If approved, Tivicay would become the first second-generation integrase inhibitor available to eligible newborns in the EU.
- The committee also recommends a new Dovato dispersible tablet formulation for children aged at least three months weighing 6 kg to less than 25 kg, along with an expansion of the existing tablet indication to children weighing at least 20 kg. Supporting studies showed safety and tolerability consistent with established profiles.
- European Commission decisions are expected in Q1 2027. A pediatric regulatory application for Dovato is also under FDA review, with a decision expected in Q1 2027.
|
|
| 04:01 |
CYTK Cytokinetics wins FDA label update for MYQORZO with Phase 3 MAPLE-HCM data
(56.13 )
|
|
- FDA approved a supplemental NDA updating MYQORZO's U.S. prescribing information to include Phase 3 MAPLE-HCM data comparing aficamten with metoprolol monotherapy in symptomatic obstructive HCM.
- Cytokinetics said MYQORZO is now the only cardiac myosin inhibitor with U.S. label data comparing its effectiveness to a beta blocker.
- In MAPLE-HCM, MYQORZO met the primary endpoint on change in peak oxygen uptake at Week 24 and significantly improved five of six secondary endpoints.
- The label continues to carry a boxed warning for risk of heart failure and the drug remains available only through the MYQORZO REMS program.
|
|
| 04:01 |
ACRS Aclaris initiates Phase 2b modzatinib trial in lichen planus
(3.92 )
|
|
- Aclaris started the randomized, double-blind, placebo-controlled Phase 2b A LP HA trial of modzatinib in moderate-to-severe lichen planus, with the first cohort in oral erosive lichen planus.
- The study will evaluate two dose levels versus placebo in about 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts.
- Primary endpoints are disease activity score changes at Week 16 for oral erosive and cutaneous cohorts and Week 24 for lichen planopilaris.
- Top-line results from the oral erosive lichen planus cohort are expected in 2H27.
|
|
| 04:01 |
ACRS Aclaris says Phase 2 ADMIRATION trial of bosakitug missed primary endpoint in atopic dermatitis
(3.92 )
|
|
- The Phase 2 trial did not meet its primary endpoint of percent change in EASI score from baseline at Week 24, and it also missed secondary endpoints.
- Aclaris said pharmacodynamic data showed robust TSLP target engagement and downregulation of Th1, Th2 and Th17 immune activation biomarkers.
- Bosakitug was generally well tolerated in the study.
- The company said development priorities remain focused on oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052.
|
|
| 04:01 |
RLMD Relmada names former Ferring urology executive Jrn Skibsted Jakobsen chief development officer
(4.21 )
|
|
- Relmada appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology.
- Jakobsen most recently served as Vice President and Therapeutic Area Head, Urology & Uro-Oncology, at Ferring Pharmaceuticals, where he led the pivotal ADSTILADRIN global clinical development program.
- Relmada said he will lead clinical development across the pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.
- Jakobsen previously served as Chief Urologist at Herlev University Hospital in Denmark.
|
|
| 04:01 |
PONY Pony.ai launches fully driverless robotaxi service with Toyota in Guangzhou
(4.46 +0.03)
|
|
- Pony.ai and Toyota launched fully driverless commercial service for the Gen-7 bZ4X Robotaxi in Guangzhou.
- The companies said the model is being tested for deployment in other major Chinese cities, with a plan to deploy around 1,000 bZ4X robotaxis across China.
- Passengers in Guangzhou can hail the service 24 hours a day through the PonyPilot app and partner mini-programs on WeChat and Alipay.
- Pony.ai said the first mass-produced vehicle rolled off the line in February 2026.
|
|
| 04:01 |
HCM HUTCHMED says China's NRDL expands coverage for ELUNATE and ORPATHYS
(14.90 +0.05)
|
|
- China's updated National Reimbursement Drug List will newly include ELUNATE for renal cell carcinoma in combination with sintilimab and ORPATHYS for EGFR-mutated NSCLC with MET amplification in combination with osimertinib.
- ORPATHYS was also renewed for metastatic or locally advanced NSCLC with MET exon 14 skipping alteration.
- HUTCHMED said ELUNATE, ORPATHYS and SULANDA will remain on the NRDL under renewed or existing multi-year agreements.
- The updated NRDL takes effect January 1, 2027.
|
|
| 04:01 |
AAPG Ascentage Pharma says lisaftoclax added to China's 2026 NRDL; olverembatinib coverage renewed
(14.62 -0.40)
|
|
- Lisaftoclax was included in China's 2026 National Reimbursement Drug List for the first time for previously treated adult CLL/SLL patients who received at least one systemic therapy including a BTK inhibitor.
- Olverembatinib's NRDL coverage was renewed for approved chronic myeloid leukemia indications.
- Ascentage said all approved indications for both core assets are now covered by the NRDL.
- The updated reimbursement list takes effect January 1, 2027.
|
|
| 04:01 |
IDYA IDEAYA nominates IDE101 as development candidate for CDKN2A-deficient solid tumors
(31.83 +0.34)
|
|
- IDEAYA named IDE101, a potential first-in-class dual CDK inhibitor, as a development candidate targeting CDKN2A-deficiency in solid tumors.
- The company said preclinical data showed activity as monotherapy and in combination with RAS and MTAP-pathway inhibitors, including its Phase 1 PRMT5 inhibitor IDE892.
- CDKN2A-deficiency occurs in about 10%-15% of solid tumors and roughly 70% of pancreatic ductal adenocarcinoma, according to the release.
- IND-enabling studies are underway to support an IND filing in H1 2027, subject to satisfactory completion of ongoing studies.
|
|
| 04:01 |
SMMT Summit Therapeutics gets FDA CRL for ivonescimab BLA in NSCLC
(14.15 -0.92)
|
|
- FDA issued a Complete Response Letter for Summit's BLA for ivonescimab plus platinum-containing chemotherapy in locally advanced or metastatic NSCLC after prior EGFR TKI therapy.
- The agency said the application cannot be approved in its present form because substantial evidence of effectiveness was not established without a statistically significant overall survival benefit.
- Summit said the Phase III HARMONi study met its progression-free survival primary endpoint, but the primary overall survival analysis showed only a positive trend.
- The company said ivonescimab plus chemotherapy showed an acceptable and manageable safety profile with no new safety signals.
|
|
| 04:01 |
AMLX Amylyx says Phase 3 LUCIDITY met primary endpoint for avexitide in post-bariatric hypoglycemia
(30.29 +0.43)
|
|
- Avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% versus placebo in the 16-week double-blind Phase 3 trial, with p=0.0000034.
- The study also met all prespecified multiplicity-controlled secondary event-rate endpoints, including 63% reduction in SMBG-confirmed Level 2 events, 47% reduction in adjudicated Level 3 events, and 42% reduction in CGM-detected Level 2 events.
- Avexitide was generally well tolerated; there were no deaths and no treatment-related serious adverse events.
- Amylyx said more than 90% of participants completed the double-blind period and all eligible participants entered the 32-week open-label extension.
|
|
| 04:01 |
RKLB Rocket Lab completes 100th Electron launch
(61.53 -2.54)
|
|
- Rocket Lab said its 100th Electron mission successfully deployed the YAMATSUMI-II SAR Earth-imaging satellite to a 575 km low Earth orbit for iQPS.
- The company said Electron reached 100 launches faster than any other commercially developed rocket.
- This was Rocket Lab's 11th Electron launch for iQPS with 100% mission success since 2023.
- iQPS has booked seven more dedicated Electron launches through 2030.
|
|
| 04:01 |
ZLAB Zai Lab says KarXT and VYVGART Hytrulo added to China's 2026 NRDL
(24.60 -1.44)
|
|
- Zai Lab said five commercial medicines in China were included in the 2026 National Reimbursement Drug List, with first-time listings for KarXT in schizophrenia and VYVGART Hytrulo in generalized myasthenia gravis.
- The company also secured renewals for NUZYRA, QINLOCK and AUGTYRO.
- The updated NRDL takes effect January 1, 2027.
- Zai Lab said the additions expand patient access to two key growth products in China.
|
|
| 04:01 |
CNS Cohen & Steers realty indexes to add American Healthcare REIT (AHR), remove VICI Properties (VICI)
(71.35 -0.07)
|
|
- Changes to the RMP, GRM and IRP indexes are effective at the close on November 20, 2026.
- RMP and GRM will add American Healthcare REIT and remove VICI Properties.
- GRM and IRP will add Great Portland Estates and remove Derwent London; IRP will also add The GPT Group and remove Mapletree Pan Asia Commercial Trust.
- The indexes are free-float adjusted, modified market-cap weighted real estate equity benchmarks.
|
|
| 04:01 |
DAN Dana tenders accepted $357.9 mln of 2030 and 2032 senior notes
(23.90 +0.64)
|
|
- Dana said its any-and-all cash tender offers for 4.250% senior notes due 2030 and 4.500% senior notes due 2032 expired on November 13.
- A total $357.873 mln aggregate principal amount was validly tendered and accepted, including $181.151 mln of 2030 notes and $176.722 mln of 2032 notes.
- Consideration was set at $975.28 per $1,000 principal for the 2030 notes and $976.35 per $1,000 principal for the 2032 notes, plus accrued interest.
- Settlement is scheduled for November 17, 2026.
|
|
| 04:01 |
AZN AstraZeneca's IMFINZI regimen wins US approval in muscle-invasive bladder cancer
(184.45 +0.07)
|
|
- FDA approved perioperative IMFINZI with neoadjuvant enfortumab vedotin-ejfv, followed by adjuvant IMFINZI, for adults with muscle-invasive bladder cancer who are ineligible for or refused cisplatin-based chemotherapy.
- Approval was based on the Phase III VOLGA trial, where the regimen cut recurrence/progression/not undergoing surgery/death risk by 49% and reduced death risk by 42% versus radical cystectomy with or without approved adjuvant treatment.
- Estimated two-year event-free survival was 64% versus 45%, and estimated two-year overall survival was 78% versus 69%.
- Regulatory reviews are also ongoing in the EU, Japan and other countries.
|
|
| 04:01 |
SPGI S&P MidCap 400 to add Chime Financial (CHYM), replacing NorthWestern Energy (NWE)
(473.59 +5.08)
|
|
- The index change takes effect before the open on November 18.
- NorthWestern Energy is being removed after its acquisition by Black Hills (BKH).
- The combined company is expected to remain in the S&P MidCap 400 and be renamed Bright Horizon Energy (HZN).
|
|
|
|
|
| 18:01 |
WRAPX This week's biggest % gainers/losers |
|
The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume). This week's top % gainers - Healthcare: PEPG (4.36 +76.52%), SPRY (3.89 +39.43%), DCTH (20.55 +37.64%), TMCI (5.27 +30.77%), LQDA (57.41 +29.30%), OBIO (7.25 +27.64%)
- Materials: GEVO (1.83 +31.65%)
- Industrials: ZIP (5.51 +46.54%), SBC (7.35 +45.83%), MOD (135.66 +40.42%), AAON (80.25 +40.32%), BW (4.56 +40.31%)
- Consumer Staples: LINC (22.81 +29.16%)
- Information Technology: NUAI (3.20 +54.59%), TLS (7.35 +52.49%)
- Communication Services: ANGX (4.60 +35.69%), NMAX (9.58 +30.52%)
- Energy: GFR (7.74 +38.21%)
- Financials: AGBK (6.26 +28.81%)
- Real Estate: FRMI (2.61 +66.24%)
This week's top % losers - Healthcare: JANX (11.37 -35.51%), IBRX (6.02 -30.32%), CADL (6.20 -29.14%), IONS (29.06 -26.28%), HIMS (19.73 -24.12%)
- Materials: LWLG (3.21 -26.54%), JBI (3.55 -23.49%), MUX (11.90 -23.13%), LAC (1.49 -22.80%)
- Industrials: ADIG (10.09 -44.92%), ENVX (1.60 -42.03%), PAYS (9.52 -35.19%), AGLT (7.36 -25.66%), PLUG (1.11 -23.45%)
- Consumer Discretionary: PSNY (3.24 -23.94%)
- Information Technology: APPS (7.61 -26.69%), VISN (4.24 -22.91%)
- Communication Services: BZ (12.96 -26.57%)
- Financials: NAVI (6.23 -26.01%), LU (7.21 -22.81%)
|
|
| 17:56 |
AEP AEP unit Kentucky Power seeks PSC approval for TeraWulf-backed generation, transmission buildout in Kentucky
(129.18 +0.27)
|
|
- Kentucky Power filed with the Kentucky PSC for approval of new generation and transmission projects tied to TeraWulf's planned Muskie Data Campus in Grayson.
- The utility said the agreement could provide more than $500 mln of fixed-cost rate offsets over its life and $100 mln of winter bill credits for residential customers starting in 2029 over the first 10 years.
- Plans include a new 760-MW combined-cycle natural gas plant near Big Sandy in Louisa and a new transmission substation; TeraWulf's campus is expected to scale to as much as 1 GW of contracted demand by 2029.
- The generation and transmission projects each need separate Certificates of Public Convenience and Necessity; PSC decisions could come as early as mid-2027.
|
|
| 17:26 |
DOUG Douglas Elliman names Heather Capriola CFO as James Kirkland retires - 8-K filing
(1.65 -0.05)
|
|
- Douglas Elliman appointed Heather Capriola as executive vice president, treasurer and CFO effective Nov. 13, filling the vacancy created by James Kirkland's retirement.
- Capriola has been with the company for more than three years and currently serves as vice president of finance and CFO of subsidiary Douglas Elliman Realty.
- Kirkland's separation terms include one year of $650,000 base salary, a prorated 2026 bonus of $369,253, a $150,000 retention payment, and accelerated vesting of 447,708 restricted shares.
- The filing said Capriola will continue to receive her current compensation and benefits and no new material plan, contract, or award was made in connection with the appointment.
- SEC filing
|
|
| 17:00 |
TNL Travel + Leisure opens first Sports Illustrated resort in Nashville, launches national hospitality brand
(78.65 +0.41)
|
|
- Travel + Leisure opened the 185-suite Sports Illustrated Resorts Nashville on Music Row, marking the brand's first operating property.
- The company said this is the first of four announced destinations totaling more than 800 suites and units.
- Chicago is expected to launch the full brand offering in spring 2027, followed by a phased Baton Rouge opening later in 2027 and a ground-up Tuscaloosa resort in 2028.
- Travel + Leisure operates Sports Illustrated Resorts under a license from Authentic Brands Group; Baton Rouge is planned as the first property to combine the vacation club, hotel and condominium residences.
|
|
| 16:57 |
WHF WhiteHorse Finance to redeem all $34.5 mln of 7.875% notes due 2028 on Dec. 15
(8.26 -0.05)
|
|
- WhiteHorse Finance will redeem 100% of its outstanding 7.875% notes due 2028, or $34.5 mln aggregate principal, on Dec. 15, 2026.
- Redemption price is $25 per note plus accrued and unpaid interest to, but excluding, the redemption date; the Dec. 15 quarterly interest payment will be paid separately to holders of record on Dec. 1.
- The notes, which trade as WHFCL, will be delisted from the Nasdaq Global Select Market after the redemption.
- WhiteHorse Finance said it expects to fund the redemption with net proceeds from additional indebtedness it intends to incur.
|
|
| 16:45 |
XYL Xylem authorizes new $1.5 bln share repurchase program
(94.18 +0.15)
|
|
- Board approved a new common-stock buyback authorization of up to $1.5 bln, effective immediately.
- Repurchases may be made from time to time in the open market or through privately negotiated transactions.
- Xylem said it plans to be opportunistic based on market conditions and other factors, and may suspend or discontinue the program at any time.
|
|
| 16:45 |
BOC Boston Omaha boosts share repurchase authorization to $85 mln from $30 mln - 8-K filing
(13.71 0.00)
|
|
- Board increased the Class A buyback program on Nov. 11; repurchases can be made in the open market, including under a Rule 10b5-1 plan, or through other methods.
- The program now expires on the earlier of Dec. 31, 2027 or when $85 mln of Class A stock has been repurchased; the company is not obligated to buy any specific number of shares.
- Boston Omaha said it repurchased 457,308 Class A shares for $6.4 mln during 2026 through Sept. 30.
- SEC filing
|
|
| 16:45 |
SB Safe Bulkers raises quarterly common dividend 20% to $0.09/share - 6-K filing
(8.29 +0.18)
|
|
- Board declared a quarterly cash dividend of $0.09/share on common stock, up from $0.075/share.
- The dividend was announced with Q3 results, as net income rose to $39.0 mln from $17.8 mln a year earlier.
- Q3 net revenue increased to $91.0 mln from $73.1 mln in the prior-year period.
- SEC filing
|
|
| 16:45 |
CNK Cinemark declares quarterly cash dividend of $0.09/share - 8-K filing
(40.80 -0.66)
|
|
- Board declared a quarterly cash dividend of $0.09/share.
- Dividend is payable December 9, 2026, to shareholders of record on November 25, 2026.
- The disclosure was made in an 8-K filing with the press release attached as Exhibit 99.1.
- SEC filing
|
|
| 16:33 |
BOW Bowhead Specialty CFO Brad Mulcahey to depart in April 2027 - 8-K filing
(34.13 +0.10)
|
|
- Bowhead Specialty disclosed that CFO and Treasurer Brad Mulcahey told the company he plans to leave in April 2027.
- Mulcahey is expected to remain in the CFO and Treasurer roles through his departure date.
- The company said the planned departure is not tied to any disagreement over operations, policies, or practices.
- SEC filing
|
|
| 16:23 |
INCY Incyte scraps planned Phase 3 MAESTRA-3 ovarian cancer study for INCB123667 - 8-K filing
(120.97 -0.73)
|
|
- Incyte will not proceed with the planned Phase 3 MAESTRA-3 trial of selective CDK2 inhibitor INCB123667 plus bevacizumab as first-line maintenance therapy in ovarian cancer.
- The study had been expected to begin in 4Q26.
- The company said the decision reflects clinical portfolio prioritization, not any safety or efficacy findings from the INCB123667 program.
- Incyte said the change is not expected to affect financial guidance or its previously disclosed long-term outlook.
- SEC filing
|
|
| 16:23 |
SAM Boston Beer enters 10b5-1 plan to repurchase up to $37.5 mln of stock - 8-K filing
(221.82 +2.20)
|
|
- Boston Beer adopted a 10b5-1 plan to buy back up to $37.5 mln of Class A common stock.
- Repurchases are scheduled to run from December 28, 2026 through March 26, 2027.
- The disclosure was made in an 8-K filed November 13, with the plan entered into on November 9.
- SEC filing
|
|
| 16:22 |
WRAPX Closing Stock Market Summary |
|
The Nasdaq Composite fell 0.9%, the S&P 500 slipped 0.4%, and the Russell 2000 declined 0.3%. They all finished above their session lows, but the market never fully recovered from an early retreat led by semiconductors and the broader AI infrastructure trade. Rising Treasury yields and persistent inflation concerns remained important constraints, particularly for growth and other higher-valuation stocks. Semiconductors established their lows early, with the Philadelphia Semiconductor Index (-3.4%) down as much as 6.5%. NVIDIA (NVDA 162.85, -3.34, -2.0%), Advanced Micro Devices (AMD 534.06, -51.24, -8.8%), Broadcom (AVGO 347.01, -17.35, -4.8%), Intel (INTC 59.66, -1.54, -2.5%), Micron (MU 778.31, -20.13, -2.5%), and Applied Materials (AMAT 370.50, -10.45, -2.7%) were notable laggards. The group contended with profit-taking, uncertainty surrounding NVIDIA's leadership, possible chip-export restrictions, analyst downgrades, and questions about the pace and execution of AI buildouts. Weakness also extended to the likes of Dell (DELL 344.28, -26.89, -7.2%), Corning (GLW 114.06, -5.16, -4.3%), Cisco (CSCO 95.64, -6.37, -6.2%), Oracle (ORCL 125.37, -1.74, -1.4%), and Seagate Tech (STX 528.29, -16.85, -3.1%). The selling was broader than technology, but it was less severe away from the Nasdaq's growth-heavy areas. Advancers outpaced decliners by a small margin at the NYSE. The equal-weighted S&P 500 (+0.2%) recovered from an early decline and turned positive during the afternoon. The information technology sector declined 1.7%, while six of the other ten S&P 500 sectors were higher. Consumer staples led the winners with a 1.4% gain and was followed by energy (+1.0%), financials (+0.8%), health care (+0.6%), utilities (+0.4%), and communication services (+0.3%). The October Producer Price Index initially generated relief because the headline reading was softer than expected, but that response faded as investors considered upward revisions to September and still-elevated year-over-year readings. Final demand prices were up 6.5% from a year ago, the largest increase since November 2022, while core producer prices were up 5.0%. Wholesale inflation remains a big problem, and that fit with the comments from New York Fed President Williams (permanent FOMC voter) and Chicago Fed President Goolsbee (2027 FOMC voter), who said the Fed has more work to do to get inflation back to the Fed's 2.0% target. Treasury yields initially dipped following the PPI report but reversed higher as the session progressed, reinforcing the pressure on technology and higher-beta stocks. The 2-yr yield settled one basis point higher at 4.89%, while the 10-yr yield rose five basis points to 5.15%, its highest settlement in more than four weeks. For the week, those yields increased 36 and 29 basis points, respectively, as speculation about a potential 50-basis-point rate hike in December contributed to sizable losses across the Treasury curve. Today's close showed that the day's weakness was concentrated most heavily in technology, but the unfavorable inflation and rate backdrop kept the broader market from mounting a sustained recovery. Attention now turns to next week's data and earnings calendar. October retail sales and the minutes from the October FOMC meeting will provide additional insight into consumer resilience and the policy outlook. Home Depot (HD 348.69, +0.43, +0.1%) and Walt Disney (DIS 118.97, +0.74, +0.6%) report Tuesday morning, followed by NVIDIA that evening. - Russell 2000: +12.4% YTD
- S&P 400: +11.4% YTD
- S&P 500: +10.5% YTD
- DJIA: +8.8% YTD
- Nasdaq Composite: +8.2% YTD
Reviewing today's data: - October PPI 0.3% vs. 0.4% Briefing.com consensus; prior revised to 1.4% from 1.3%
- October Core PPI 0.3% vs. 0.3% Briefing.com consensus; prior revised to 0.8% from 0.7%
- 11/07 EIA Natural Gas Inventories +61 bcf; prior +77 bcf
Monday's economic calendar: - 8:30 AM ET: November Empire State Manufacturing; Briefing.com consensus 15.9; prior 25.5
|
|
| 16:20 |
SKYA SkyAI posts preliminary tender results; expects to buy about $209 mln of stock and warrants
(2.32 -0.13)
|
|
- SkyAI said its cash tender offer expired Nov. 12 and, based on a preliminary count, it expects to purchase about 47.0 mln common shares plus multiple warrant classes tendered and not withdrawn.
- Expected purchases include about 5.1 mln cash pre-funded warrants, 10.5 mln cryptocurrency pre-funded warrants and 3.9 mln strategic warrants at $3.00 each less the $0.0001 exercise price.
- SkyAI also expects to buy about 34.5 mln cash stapled warrants and 21.5 mln cryptocurrency stapled warrants at $0.17 each; aggregate purchase price is expected to be about $209 mln, excluding fees and expenses.
- Results remain preliminary and subject to the depositary's confirmation process; SkyAI said final accepted amounts will be announced later and payment will occur promptly under the offer terms.
|
|
| 16:15 |
EBC Eastern Bankshares names Peter Markell lead independent director effective Jan. 1, 2027
(22.88 +0.12)
|
|
- Markell will succeed Deborah Jackson as lead independent director on Jan. 1, 2027; Jackson plans to step down from the role ahead of her expected board retirement at year-end 2027.
- Markell has served on the board since 2006 and currently chairs the Audit Committee; he is CFO of Brown University Health and previously was CFO and treasurer of Mass General Brigham.
- Eastern also said Chair Emeritus Richard Holbrook will retire from the board effective Dec. 31, 2026 under mandatory age limits, and director Luis Borgen will resign effective Dec. 31, 2026.
|
|
| 16:10 |
NMRK Newmark advises on 55 Broad Street JV recapitalization, $305 mln financing
(10.62 -0.18)
|
|
- Newmark said it arranged the recapitalization and $305 mln loan financing for 55 Broad Street, a newly completed 571-unit multifamily property in Downtown Manhattan.
- The transaction includes RXR acquiring a minority interest in the property at a valuation above $500 mln; Silverstein Properties and MetroLoft bought the asset in 2023 and converted it from office to residential use.
- Wells Fargo provided the loan to the new joint venture entity.
- The 35-story property totals 352,096 square feet and includes 428 market-rate units, 143 affordable apartments and about 8,340 square feet of ground-floor retail space.
|
|
| 16:08 |
BMI Badger Meter approves additional share repurchase authorization for up to $250 mln of outstanding common stock
(154.62 +1.03)
|
|
|
|
| 16:05 |
WCCB West Coast Community Bancorp authorizes $25 mln share repurchase program
(63.50 +0.14)
|
|
- West Coast Community Bancorp's board approved a new program to repurchase up to $25 mln of common stock.
- Repurchases may be made in the open market or through privately negotiated transactions, but the program does not require the company to buy any set number of shares.
- The authorization runs through Dec. 31, 2028 and is subject to customary regulatory approvals or non-objections.
- The company said the program may be suspended, modified or terminated at any time without notice.
|
|
| 16:05 |
MANU Manchester United names Mauricio Pochettino men's first-team head coach
(22.42 -0.42)
|
|
- Pochettino agreed to take over as Manchester United men's first-team head coach on Nov. 18.
- Manchester United said it reached an agreement with the U.S. Soccer Federation to release Pochettino and his staff after they complete their U.S. Men's National Team responsibilities.
- Pochettino most recently led the U.S. Men's National Team to the Round of 16 at the FIFA World Cup and previously managed Tottenham Hotspur, Paris Saint-Germain and Chelsea.
|
|